Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparation News provided by Share this article Share this article BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company's Sawston, UK advanced manufacturing facility has been completed and the fac...
Source: prnewswire.com